• Printer Friendly Version
  • Decrease Text Size
  • Increase Text Size
  • PDF

Thoracic Center

Thoracic Center

The Redl Center For Cancer Care provides a specialized thoracic cancer program that is dedicated to bringing the most current diagnostic and treatment modalities to the Hudson Valley.

Our thoracic cancer program brings together physician specialists in radiology, pathology,medical oncology, radiation oncology, and thoracic surgery to collaborate on the individualized treatment of a person who has benign or malignant lung, mediastinal or pleural conditions.

The thoracic cancer program focuses on providing the most current diagnostic technology in an expedited manner to facilitate rapid treatment.  The physician specialists meet weekly in a multidisciplinary meeting known as tumor conferences to discuss and review all lung cancer cases to reach consensus on optimal treatment approaches.

  • Small cell lung cancer
  • Non-small cell lung cancer
  • Mediastinal masses
  • Lung nodules
  • Chest wall tumors
  • Mesothelioma/Pleural diseases
  • Metastic diseases to lung
  • Esophageal Cancer

Radiology

  • CT scan, including low-dose screening chest CT
  • CT guided needle biopsy
  • Magnetic Resonance Imaging (MRI)

Pulmonology

  • Pulmonary function tests
  • Flexible bronchoscopy
  • Endobronchial Ultra Sound

Pathology

  • Histopathology of lung biopsy specimens
  • Cytology of bronchoscopy and fine needle aspirates
  • Immunohistochemical testing of tumor markers
  • Flow cytometry

Thoracic Surgery

  • Minimally invasive surgery
  • Mediastinoscopy
  • Thoracoscopy
  • Thoracotomy

The Redl Center For Cancer Care is an accredited participant in the Cancer Trials Support Unit (CTSU), a federally-funded service of the National Cancer Institute. Our participation in this program enables physicians in the lung cancer program to enroll their patients in nation-wide and international Phase III NCI-funded cancer research trials.

Participating in these trials allows patients in the lung cancer program access to treatments otherwise not available or not yet approved for general clinical use.